The next MJ Play!!!!  CTCO -CANNABIS THERAPY CORP. -

New Post Public Reply Private Reply Replies (0) Message Board
subflyer8
The next MJ Play!!!!  CTCO -CANNABIS THERAPY CORP.

- CTCO is issing a Dividend! 0.5 for every share you own! Must be in by 03/28/2014

See 8k: http://www.otcmarkets.com/edgar/GetFilingHtml...ID=9876847

Current OS:
O/S: 46,875,331
Float: 23,819,333
A/S: ?

Following the Smith Share Cancellation we will have 46,875,331 shares issued and outstanding and the 25,055,998 shares will represent approximately 53.5% of our issued and outstanding shares.

See recent 8k dated March 14, 2014 item 5.01 on page 2:

http://www.otcmarkets.com/edgar/GetFilingHtml...ID=9857349

Who are the players?

Company Officers/Contacts

President, CEO

Soren Mogelsvang

PhD, Founder and VP of Research and Development
15 years experience in discovery and translational research from various positions in biotech and academia. Dr. Mogelsvang holds a Ph.D. degree from the University of Cambridge, England, and received postdoctoral training at the University of Colorado School of Medicine.

CFO, Secretary, Treasurer

Arnold Tinter

Was appointed as Director, Chief Financial Officer and Secretary on January 10, 2012. Mr. Tinter founded Corporate Finance Group, Inc., a consulting firm located in Denver, Colorado, in 1992, and is its President. Corporate Finance Group, Inc, is involved in financial consulting in the areas of strategic planning, mergers and acquisitions and capital formation. He provides Chief Financial Officer (CFO) services to a number of public companies, including Barfresh Food Group Inc., LifeApps Digital Media Inc. and Arvana Inc. From 2006 to 2010 he has provided CFO services to Spicy Pickle Franchising, Inc., a public company, where his responsibilities included oversight of all accounting functions, including SEC reporting, strategic planning and capital formation. From May 2001 to May 2003, he served as CFO of Bayview Technology Group, LLC, a privately held company that manufactured and distributed energy-efficient products. From May 2003 to October 2004, he served as that companys Chief Executive Officer. Prior to 1990 Mr. Tinter was Chief Executive Officer of Source Venture Capital, a holding company with investments in the gaming, printing, retail industries. Mr. Tinter currently serves as a director of Lifeapps Digital Media Inc., a public company. Mr. Tinter received a B.S. degree in Accounting in 1967 from C.W. Post College, Long Island University, and is licensed as a Certified Public Accountant in Colorado.

http://www.forbes.com/profile/arnold-tinter/

Company Directors:

Vered Caplan -

age 45, has been the Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes since 2008. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the past five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in bio-medical engineering from Tel-Aviv University specialized in signal processing; management for engineers from Tel-Aviv University specialized in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialized in software and cad systems.

http://www.kamedis.com/kamedis-worldwide.html

Dr. Cohava Gelber

Founder and Executive Chairperson
Over 25 years experience in various executive positions in biotech and pharmaceutical companies (ImmuLogic Pharmaceutical Corp., Molecular Discoveries, MannKind Corp.); drug discovery and product development experience from non clinical stages, IND, through clinical development up to phase III clinical trials; secured over $500MM of federal funding; authored over 70 patents/patent applications; PhD from the Weizmann Institute, Post Doctorate at Stanford University and MBA from Cornell University.

Guy Yachin

Engineer and MBA, President & CEO
Entrepreneur and CEO of multiple biomedical companies; raised ~$100MM as CEO and Co-founder of Chiasma (announced a 600MM deal with Roche in February 2013) and MGVS (led it through a mega-deal with Teva Pharmaceuticals); has been an active board member of several successful private and public companies, among them Orgenesis (ORGS), Enzymotec, Remon Medical (acquired by BSC) and NanoPass.

New Articles out:

http://www.crainsnewyork.com/article/20140326...es-to-pot#

http://www.stockhouse.com/news/natural-resour...o-next-gen

http://marijuanaindex.org/2014/03/cannabis-th...s-new-ceo/

http://www.biomedreports.com/20140324175106/c...f-ceo.html
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 133

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 91

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Epic Yoga Event by Real Essentials to Support Ovarian Cancer

Updated Category News Views 70

Real Essentials Teams Up for Ovarian Cancer Awareness To honor Ovarian Cancer Awareness Month, Real Essentials, a brand celebrated for its affordable yet high-quality apparel, partnered with Not These Ovaries, a nonprofit organization dedicated to ovarian cancer. Together, they created a unique yoga event that aimed to raise both awareness and funds for essential ovarian...

Continue Reading
MKDWELL Tech Inc. Posts H1 2024 Financial Results Drop

Updated Category News Views 115

MKDWELL Tech Inc. Financial Overview for 2024 MKDWELL Tech Inc. (NASDAQ: MKDW), a key player in the automotive electronics industry with operations in Mainland China and Taiwan, has provided an update on its financial status for the first half of the fiscal year. The latest results show a significant decline in revenue compared to the same period in the previous year....

Continue Reading
Northwest Pipe Company Strengthens Production with New Facility

Updated Category News Views 212

Northwest Pipe Company Enhances Production Capacity Northwest Pipe Company, renowned for its expertise in water-related infrastructure, has announced a significant upgrade to its production facilities. The company has recently inaugurated a new precast concrete pipe and manhole manufacturing plant aimed at addressing the rising demand in the region. With this strategic...

Continue Reading
Allient Inc. Posts Third Quarter Gains Driven by Initiatives

Updated Category News Views 99

Allient Inc. Announces Impressive Third Quarter Results Allient Inc. (NASDAQ: ALNT), a global leader in precision and specialty Motion, Controls and Power products, has announced significant financial results for its third quarter. Despite facing challenges in key industrial and vehicle markets, the company has demonstrated resilience through its operational improvements...

Continue Reading
Fulcrum Therapeutics Investor Event to Unveil PIONEER Findings

Updated Category News Views 191

Introduction to Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a pioneering biopharmaceutical company, is dedicated to enhancing the lives of individuals grappling with genetically defined rare diseases. Their primary focus is on developing innovative small molecules that target specific diseases at their root cause. This commitment drives their latest...

Continue Reading